CorMedix Inc. — Director's Dealing 2014

Jan 14, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2014-01-10

Reporting Person: MILBY RANDY (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-01-10	Stock Option (right to buy)	$2.02	A	100000	Acquired	2024-01-09	Common Stock, $0.001 par value per share (100000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 par value per share	142857	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C-3 Non-Voting Convertible Preferred Stock	$1		Common Stock, $0.001 par value per share (237000)	23700	Direct
Warrant (right to purchase Common Stock)	$1.25	2020-01-08	Common Stock, $0.001 par value per share (118500)	118500	Direct
Series C-3 Non-Voting Convertible Preferred Stock	$1		Common Stock, $0.001 par value per share (13000)	1300	Indirect
Warrant (right to purchase Common Stock)	$1.25	2020-01-08	Common Stock, $0.001 par value per share (6500)	6500	Indirect
Stock Option (right to buy)	$0.9	2023-03-20	Common Stock, $0.001 par value per share (500000)	500000	Direct
Stock Option (right to buy)	$0.68	2022-12-05	Common Stock, $0.001 par value per share (100000)	100000	Direct
Warrant (right to purchase Common Stock)	$0.4	2017-09-20	Common Stock, $0.001 par value per share (125000)	125000	Indirect
Stock Option (right to buy)	$0.29	2022-05-14	Common Stock, $0.001 par value per share (50000)	50000	Indirect

Footnotes

F1: The reporting person beneficially owns these securities through his ownership interest in MW Bridges LLC (an entity through which he has voting and investment control).

F2: The option vested 100% on January 10, 2014.

F3: On January 8, 2014, the reporting person acquired in a private placement (i) 23,700 shares of the Company's Series C-3 Non-Voting Convertible Prefered Stock, each share is convertible into 10 shares of the Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase Common Stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.

F4: On January 8, 2014, the reporting person, through his ownership in MW Bridges LLC (an entity through which he has voting and investment control), acquired in a private placement (i) 1,300 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of the Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase Common Stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.

F5: These options vest based on performance milestones running through December 31, 2014.

F6: These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.

F7: On September 20, 2012, the reporting person, through his ownership in MW Bridges LLC (an entity through which he has voting and investment control), acquired in a private placement $50,000 of (i) 9% Senior Convertible Notes, convertible into shaers of the Company's Common Stock, $0.001 par value per share, at a conversion price of $0.35 per share, which were converted on September 20, 2013; and (ii) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.

F8: These options vested 100% upon receipt of CE Mark approval for the Company's Neutrolin product candidate on July 5, 2013.